Thesis--University of Umeå, 1981. / Extra t.p. with thesis statement inserted. Includes four of the author's published papers. Includes bibliographies.

Thesis--University of Umeå, 1981. / Extra t.p. with thesis statement inserted. Includes four of the author's published papers. Includes bibliographies.

Thesis (M.S.)--University of Delaware, 2007. / Principal faculty advisors: Robert A. Sikes and Randall Duncan, Dept. of Biological Sciences. Includes bibliographical references.

Thesis (Ph. D.)--University of Wisconsin--Madison, 1970. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliography.

No description available.

An investigation of the ratio of free to bound phenytoin in overdose cases was accomplished by three studies to answer these questions: 1. Will the free to bound ratio change with increasing total phenytoin concentration? 2. Will the free to bound ratio be altered with decreasing total protein concentration? 3. Do these results correlate with overdose cases? The results demonstrated that the ratio of free to bound phenytoin remains constant throughout the therapeutic range as long as a person has a normal total protein concentration. However, the free to bound ratio changes significantly when the total protein decreases by 25 per cent. This substantiates the importance of monitoring free and total phenytoin concentrations in hypoproteinemia.

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

The crystallization kinetics of diphenylhydantoin (DPH) has been studied at constant conditions in a small mixed suspension mixed product removal (MSMPR) crystallizer. Supersaturation is created by changing the pH of a DPH solution in the crystallization vessel. Crystal size distributions (CSD's) are measured by an in situ zone sensing method. Effects of pH and supersaturation on crystallization kinetics and CSD are summarized. The effect of an additive on the crystal growth of DPH has been studied in a batch system. Avoidance of nucleation in the early stages of crystallization is essential to the effect investigated.

Dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Science In Medicine / The interaction between miglitol, an a-glucosidase inhibitor used as an adjunct therapy in diabetes, and phenytoin, an anticonvulsant primarily used in the treatment of epilepsy, was studied over 26 days. Twenty-four healthy male volunteers took part in a placebo controlled, double blind, cross-over study in two phases, to determine the effects of multiple 100mg doses of miglitol on a single 400mg dose of phenytoin sodium. Miglitol or placebo was administered three times daily from Day 1 to Day 5. Phenytoin was administered as a single dose on Day 3 of each phase, after which blood samples were taken at regular intervals. A washout period of 14 days separated the two phases. / IT2018

Embryonic exposure to the anticonvulsant drug Dilantin has been shown to have detrimental effects on development. Some of the observed effects include growth retardation, craniofacial defects, and even death. As the drug is metabolized, toxic intermediates form, which could be causing the characteristic abnormalities observed in embryos exposed to Dilantin. Culture of preimplantation mouse embryos in the presence of IOµg/mL or 20µglmL Dilantin show a slowing of development inl9.3% and 19.1% ofembryos respectively at Day 3 of culture. The toxic intermediates could be causing alterations in cyclin expression, cell cycle proteins, or the cell cycle timing itself. Previous research determined an in vivo baseline expression for cyclins B 1, E, D, A and cdk2, which was used to compare the expression of these cyclins and cdks between in vivo and Dilantin cultured embryos. Altered patterns in cultured embryos suggested that an alteration in cell cycle timing, therefore, S phase timing was determined in cultured untreated embryos utilizing 5'-Bromo-2-deoxyuridine (BrdU) incorporation and indirect immunofluorescence staining. The results of the experiment showed the second S phase was at 30 hpf, approximately 9 hours later, and the third S phase was at 54 hpf, approximately 3 hours later than previous in vivo literature reports. S phase timing in NaOH vehicle controls did not appear different from untreated controls. Dilantin showed S phase peaks at 24 and 55 hpf. In the Dilantin treated embryos, the nuclear staining intensity for the second S phase did not decrease as rapidly as had been observed in control embryos. Embryos that developed beyond the 2-cell stage demonstrated two distinct S phase peaks at 45 and 54 hpf, while embryos at the 2-cell stage did pass through the second S phase but not the third S phase. These data suggested that the Dilantin could be causing a delay in G2. Future experiments would be necessary to determine if the expression of G2 cyclins are being altered in Dilantin treated embryos. / Department of Biology